1. Home
  2. SRTS vs ICCC Comparison

SRTS vs ICCC Comparison

Compare SRTS & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sensus Healthcare Inc.

SRTS

Sensus Healthcare Inc.

HOLD

Current Price

$4.06

Market Cap

67.5M

Sector

Health Care

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$5.00

Market Cap

55.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTS
ICCC
Founded
2010
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5M
55.5M
IPO Year
2016
1987

Fundamental Metrics

Financial Performance
Metric
SRTS
ICCC
Price
$4.06
$5.00
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
170.7K
17.9K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$35,609,000.00
$27,769,304.00
Revenue This Year
N/A
N/A
Revenue Next Year
$47.33
N/A
P/E Ratio
N/A
$18.36
Revenue Growth
N/A
16.49
52 Week Low
$3.03
$4.10
52 Week High
$9.31
$7.60

Technical Indicators

Market Signals
Indicator
SRTS
ICCC
Relative Strength Index (RSI) 53.57 40.21
Support Level $3.81 $4.70
Resistance Level $4.34 $5.36
Average True Range (ATR) 0.29 0.28
MACD -0.03 -0.01
Stochastic Oscillator 29.02 22.83

Price Performance

Historical Comparison
SRTS
ICCC

About SRTS Sensus Healthcare Inc.

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: